CL2015001246A1 - Derivados de bendamustina y los metodos de su uso - Google Patents

Derivados de bendamustina y los metodos de su uso

Info

Publication number
CL2015001246A1
CL2015001246A1 CL2015001246A CL2015001246A CL2015001246A1 CL 2015001246 A1 CL2015001246 A1 CL 2015001246A1 CL 2015001246 A CL2015001246 A CL 2015001246A CL 2015001246 A CL2015001246 A CL 2015001246A CL 2015001246 A1 CL2015001246 A1 CL 2015001246A1
Authority
CL
Chile
Prior art keywords
methods
bendamustine
bendamustine derivatives
derivatives
bendamustina
Prior art date
Application number
CL2015001246A
Other languages
English (en)
Spanish (es)
Inventor
Roger P Bakale
Peter D Brown
Jian Chen
Anthony S Drager
Rachel Y Labell
Robert E Mckean
Piyush R Patel
Renee C Roemmele
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of CL2015001246A1 publication Critical patent/CL2015001246A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015001246A 2012-11-12 2015-05-08 Derivados de bendamustina y los metodos de su uso CL2015001246A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12
PCT/US2013/069550 WO2014075035A1 (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Publications (1)

Publication Number Publication Date
CL2015001246A1 true CL2015001246A1 (es) 2016-01-15

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001246A CL2015001246A1 (es) 2012-11-12 2015-05-08 Derivados de bendamustina y los metodos de su uso

Country Status (17)

Country Link
US (7) US9452988B2 (enExample)
EP (1) EP2917183A1 (enExample)
JP (1) JP6262246B2 (enExample)
KR (1) KR20150086308A (enExample)
AR (1) AR093457A1 (enExample)
AU (1) AU2013342015B2 (enExample)
BR (1) BR112015010501A2 (enExample)
CA (1) CA2890462A1 (enExample)
CL (1) CL2015001246A1 (enExample)
EA (1) EA029706B1 (enExample)
HK (2) HK1212977A1 (enExample)
IL (1) IL238662A (enExample)
MX (1) MX2015005805A (enExample)
PH (1) PH12015501024A1 (enExample)
SG (1) SG11201503560TA (enExample)
TW (1) TWI598341B (enExample)
WO (1) WO2014075035A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2968153B1 (en) 2013-03-12 2018-05-02 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
US11071789B2 (en) * 2016-07-13 2021-07-27 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3224945C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU2002239405A1 (en) 2000-12-01 2002-06-11 Enzon, Inc. Tetrapartate prodrugs
AU2003227147A1 (en) * 2002-04-05 2003-10-27 Universite De Montreal Stealthy polymeric biodegradable nanospheres and uses thereof
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN103285395A (zh) 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
US9149441B2 (en) * 2008-09-29 2015-10-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
EP2346836B1 (en) * 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JP6209446B2 (ja) 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
WO2012059935A1 (en) 2010-11-01 2012-05-10 Shilpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
DE102010055499A1 (de) * 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
EP2656843B1 (en) 2012-04-26 2015-03-18 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
CA2875455C (en) 2012-06-19 2020-03-10 Helmut Schickaneder Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
AU2013299641A1 (en) 2012-08-10 2015-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same

Also Published As

Publication number Publication date
US9913827B2 (en) 2018-03-13
US20170182008A1 (en) 2017-06-29
US20150246023A1 (en) 2015-09-03
IL238662A0 (en) 2015-06-30
HK1212977A1 (zh) 2016-06-24
US20160016912A1 (en) 2016-01-21
US20160289198A1 (en) 2016-10-06
IL238662A (en) 2017-08-31
BR112015010501A2 (pt) 2017-07-11
AU2013342015A1 (en) 2015-05-28
US20150274675A1 (en) 2015-10-01
EA029706B1 (ru) 2018-05-31
SG11201503560TA (en) 2015-06-29
TW201439069A (zh) 2014-10-16
CA2890462A1 (en) 2014-05-15
PH12015501024A1 (en) 2015-07-27
KR20150086308A (ko) 2015-07-27
US9150517B2 (en) 2015-10-06
HK1215701A1 (zh) 2016-09-09
US20150232427A1 (en) 2015-08-20
TWI598341B (zh) 2017-09-11
AU2013342015B2 (en) 2016-11-24
JP6262246B2 (ja) 2018-01-17
EA201590925A1 (ru) 2015-09-30
US9149464B2 (en) 2015-10-06
JP2015536996A (ja) 2015-12-24
MX2015005805A (es) 2016-04-15
EP2917183A1 (en) 2015-09-16
US9452988B2 (en) 2016-09-27
US20180147186A1 (en) 2018-05-31
AR093457A1 (es) 2015-06-10
CN105051016A (zh) 2015-11-11
US9630926B2 (en) 2017-04-25
WO2014075035A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CR20150316A (es) Compuestos y sus métodos de empleo
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
UY35500A (es) Indazoles sustituidos con heteroarilo
UY36311A (es) Indazoles sustituidos con bencilo
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY36076A (es) Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
AR091837A1 (es) Compuestos para inmunoterapia dirigida
MX2015010312A (es) Metodos para tratamiento del melanoma.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.